Accreditation Information

Direct Accreditation:

            Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activityfor a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Risk Management
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study.


1. List three benefits of using apps towards helping patients towards recovery.
2. Assess at least two benefits and two risks of using technology with patients.
3. Apply the four steps from the APA app evaluation model towards making a more informed decision about whether to use a certain with a patient.

Target Audience

Primary care Physicians, Psychiatrists, Psychologists, Nurses, Residents, Allied Health professional, & Medical & PA students

Faculty Disclosure

Faculty, Planning Committee and CME Administrator disclosure statement

John Torous, Speaker, receives research support from Otsuko.

Nitigna Desai, Course Director, has no relevant financial relationships to disclose.

Sakina Flint, RSS Coordinator, has no relevant financial relationships to disclose.

Faculty Disclosure of off-label use

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product. 

Faculty Disclosure Policy

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed